Fourteen compounds and their derivatives for the treatment of diseases and injuries characterized by reduced neurogenesis and neurodegeneration. Neuronascent, Inc.: WO2007035722.
The application is in the field of adult neurogenesis and neuronal degeneration and regeneration. It aims to characterize the activity of 15 compounds and their derivatives on adult neurogenesis, apoptosis, necrosis and neuron dysfunction in vitro. The activity of the compounds and their derivatives was tested on cultures of adult human-derived neural progenitor and stem cells, in presence of staurosporine, peptide beta-amyloid and hydrogen peroxide, and was assessed by immunocytology. The compounds and their derivatives stimulate the differentiation of adult-derived neural progenitor and stem cells into the neuronal pathway, and inhibit staurosporine-induced apoptosis, peptide beta-amyloid-induced necrosis and hydrogen peroxide-induced neuron dysfunction. The application claims the use of the 15 compounds and their derivatives for the treatment of diseases and injuries particularly characterized by reduced neurogenesis and neuronal loss, including Alzheimer's disease (AD), depression, cerebral strokes and traumatic brain and spinal cord injuries.
Dublin City University, School of Biotechnology, Glasnevin, Dublin 9, Ireland. philippe.taupin@dcu.ie
Philippe
P
Taupin
D000328:Adult; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002478:Cells, Cultured; D006801:Humans; D009336:Necrosis / Q000378:metabolism; D009416:Nerve Regeneration / Q000187:drug effects*; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D055495:Neurogenesis / Q000187:drug effects*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D010330:Patents as Topic; D013234:Stem Cells / Q000187:drug effects / Q000378:metabolism